Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10203530 | 0.91 | DDB1 (0.41) | SMN1; SMN2GPR119DDB1CRBNALDH1A1 | |
| SCHEMBL10179775 | 0.91 | TLR7 (0.39) | SMN1; SMN2GPR119DDB1CRBNALDH1A1 | |
| SCHEMBL14141858 | 0.88 | SMN1; SMN2 (0.43) | SMN1; SMN2GPR119DDB1CRBNTLR7 | |
| SCHEMBL14142023 | 0.87 | EGLN1 (0.35) | ALDH1A1MAPT | |
| SCHEMBL10179612 | 0.83 | WNT3A (0.42) | SMN1; SMN2GPR119DDB1CRBNALDH1A1 | |
| SCHEMBL14142082 | 0.82 | GPR119 (0.49) | SMN1; SMN2GPR119DDB1CRBNTLR7 | |
| SCHEMBL14142264 | 0.79 | GPR119 (0.45) | SMN1; SMN2GPR119DDB1CRBNALDH1A1 | |
| SCHEMBL10179397 | 0.79 | TRPV3 (0.42) | SMN1; SMN2GPR119DDB1CRBNTLR7 | |
| SCHEMBL10203527 | 0.79 | DDB1 (0.44) | SMN1; SMN2GPR119DDB1CRBNTLR7 | |
| SCHEMBL10180870 | 0.78 | EGLN1 (0.35) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192510-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-06-27 | — | — | US | disclosed |
| EP-2532656-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192510-A1 | GPR119 AGONIST | GPR119, GPR4, GPR27 | SMN1; SMN2 3543/4885GPR119 1/4885DDB1 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.